Azenta Adds Elegen License, SynPlexity Deal to Boost GENEWIZ
Image
Burlington, Mass. – October 30, 2026 -- Azenta (Nasdaq: AZTA) has secured an exclusive license to Elegen Corp.'s cell-free DNA synthesis platform and acquired SynPlexity Inc., two moves aimed at expanding the gene synthesis and discovery capabilities of its GENEWIZ business.
Elegen license adds cell-free DNA manufacturing to the GENEWIZ portfolio
The Elegen platform is designed to improve DNA quality, delivery speed and manufacturing scalability. It supplies sequence-verified DNA constructs and templates that simplify preparation for downstream experiments, including antibody discovery.
Production workflows are compact, so regional capacity can be added close to customers as demand requires.